Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.

Bielekova B, Catalfamo M, Reichert-Scrivner S, Packer A, Cerna M, Waldmann TA, McFarland H, Henkart PA, Martin R

Proc Natl Acad Sci U S A. 2006 Apr 11; 103(15):5941-6. Epub 2006 Apr 03. PMID: 16585503. Abstract